The strong hemodynamic and sustained blood pressure response could de-risk the BACKBEAT pivotal trial; monitor enrollment and interim data readouts as key catalysts. A successful outcome could lead to rapid commercialization via Medtronic distribution.
Price Chart
Executive Summary
Orchestra BioMed presented new clinical data from its MODERATO II trial showing AVIM Therapy delivered an immediate 13.2 mmHg reduction in office systolic blood pressure, with 97% of patients achieving >5 mmHg reduction. The data, presented at HRS 2026, support the ongoing BACKBEAT pivotal trial in collaboration with Medtronic.
Key Facts
- AVIM Therapy showed an immediate average reduction of 13.2 mmHg in office systolic blood pressure (oSBP) upon activation
- 97% of patients achieved >5 mmHg reduction in oSBP
- At 6 months, 89% of patients achieved ambulatory systolic blood pressure (aSBP) <140 mmHg, and 58% achieved <130 mmHg
- Sustained blood pressure reductions observed through 3.6 years in a sub-cohort
- BACKBEAT global pivotal trial is ongoing in collaboration with Medtronic
Financial Impact
Potential to significantly increase the value of OBIO's AVIM Therapy program, especially given Medtronic partnership and FDA Breakthrough Device Designation
Risk Factors
- Clinical results are from a pre-randomization cohort and not the full randomized controlled trial endpoint
- BACKBEAT trial may not replicate these results in a larger, global population
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3280225 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 26d ago | 144 | $6.35 $5.73 | ▼ −9.76% | ▼ −11.06% | $5.78 (−8.98%) |
Oct 1, 2026 26d ago | 8-K | $6.35 $5.73 | ▼ −9.76% | ▼ −11.06% | $5.78 (−8.98%) |
Sep 22, 2026 5w ago | Institutional Cluster | $6.22 $6.08 | ▼ −2.25% | ▼ −1.06% | $5.78 (−7.07%) |
Sep 8, 2026 7w ago | Insider Cluster | $5.43 $6.04 | ▲ +11.23% | ▲ +12.35% | $5.78 (+6.45%) |
Sep 1, 2026 8w ago | 144 | $4.90 $5.45 | ▼ −11.22% | ▼ −11.14% | $5.78 (−17.96%) |
Jul 1, 2026 16w ago | 144 | $4.30 $3.96 | ▼ −7.91% | ▼ −8.17% | $5.78 (+34.42%) |
Jun 2, 2026 20w ago | Insider Cluster | $3.86 $4.02 | ▲ +4.15% | ▲ +7.96% | $5.78 (+49.74%) |
May 19, 2026 23w ago | Insider Cluster | $4.00 $4.06 | ▲ +1.50% | ▼ −0.75% | $5.78 (+44.50%) |
Apr 29, 2026 25w ago | DEFA14A | $3.99 $3.93 | ▼ −1.50% | ▼ −3.23% | $5.78 (+44.86%) |
Apr 23, 2026 26w ago | Press Release | $4.15 $3.80 | ▼ −8.43% | ▼ −9.91% | $5.78 (+39.28%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers